AOMA 2017 Fall Seminar Drug Tapering, Modification, or Discontinuation: Establishing the Lowest Effective Dose. AOMA 2017 Fall Seminar Drug Tapering

Size: px
Start display at page:

Download "AOMA 2017 Fall Seminar Drug Tapering, Modification, or Discontinuation: Establishing the Lowest Effective Dose. AOMA 2017 Fall Seminar Drug Tapering"

Transcription

1 AOMA 2017 Fall Seminar Drug Tapering, Modification, or Discontinuation: Establishing the Lowest Effective Dose Steven C. Boles, DO, FASM AOMA 2017 Fall Seminar Drug Tapering Dr. Boles has no conflicts to disclose

2 Addiction Medicine Steven C. Boles, D.O., FASAM Board Certified FP & ADM CAQ in ADM from AOBFP Fellow of ASAM (American Society of Addiction Medicine) Boards American Osteopathic Board of Family Physicians American Board of Addiction Medicine Addiction Medicine (ADM) Steven C. Boles, D.O., FASAM Adjunct Assistant Professor, Division of Clinical Education : Midwestern University Arizona College of Osteopathic Medicine (AZCOM); , ongoing President : Arizona Society of Addiction Medicine, Inc. (AzSAM) ;

3 ADM I was trained at St. Luke s Behavioral Health Center, in Phoenix, Arizona, from April 1999 to August 2000 by C.J. Shaw, M.D. (and the nursing staff). I will be forever grateful to Dr. Shaw - for that experience, - for being my mentor, - for being my friend, to this day. AA was founded in 1935 When 2 alcoholics began to talk to each other about their struggles with alcohol And found that they both stayed sober. When nothing else had worked. Bill Wilson was a stock broker Dr Robert Smith was a colorectal surgeon

4 AA was founded in 1935 What does the very famous founder of AA Bill Wilson And Osteopathic Medicine have in common? Bill Wilson s mother was a D.O.??!! Emily Griffith Wilson Bill and Dorothy s mother, Emily decided that she did not want to become a leftbehind single mother, so she obtained a divorce and made plans to go to school in Boston where she earned a degree in osteopathy leaving her children with her parents. She later trained as a psychoanalyst with Dr. Alfred Adler. She was remarried to Dr. Charles Strobel. Describing their relationship with their mother, Bill wrote neither Dorothy nor I have ever stood in quite the right relation to mother in spite of our efforts to do so. Text and picture from Bill Wilson My Name is Bill (S. Cheever p. 149)

5 Animals and Humans use addictive drugs to get high Although Chemical Abstracts lists over 15 million compounds, only a FEW score (~ 130 if one counts all the variations within each class) of these are addictive Representing 8 classes of drugs The 8 classes of addictive drugs These 8 known classes can be grouped into an Organizational Paradigm represented by 7 unrelated European working class males 1 female ringleader and their individual drugs of choice

6 Sneezy : Cocaine Dopey : Marijuana

7 Sleepy : BZD and Barbiturates (or other non-barb sedatives) Bashful : PCP & Ketamine (dissociative anesthetics)

8 Happy : Amphetamines Grumpy : Alcohol

9 Doc : Opioids Snow White: Marlboro Lights (Nicotine)

10 Mismanaged Pain Behavior can be distinguished from Addiction : When the pt seeking pain relief Receives adequate analgesia or treatment they demonstrate IMPROVED FUNCTIONING in daily living. Addicts DO NOT. Mismanaged Pain Behavior can be distinguished from Addiction : Legitimate pain pts use their medication as prescribed. Addicts DO NOT. Pain pts do not use their medications, or ANY other drugs, INCLUDING ALCOHOL, in a manner that persistently causes sedation or euphoria. ADDICTS DO THIS ALL THE TIME.

11 Problems suggesting addiction during opioid Rx : PREOCCUPATION WITH OPIOIDS - failure to comply with non-drug therapies - failure to keep appointments - shows interest only in relief of symptoms, not rehabilitation - reports no effect from non-opioid Rx s - seeks meds from multiple physicians The 5 C s suggesting addiction during opioid Rx : Continued Use Despite Adverse Consequences from Medications : - decreasing functionality - observed intoxication - increasing complaints of pain, despite titration of medications - negative affective (emotional) states

12 The 5 C s suggesting addiction during opioid Rx : Loss of CONTROL Over Medication Use - failure to bring unused medications to appointments - requests for early renewals / refills - reports lost, or stolen, prescriptions - appearance at clinic without appointment, and IN DISTRESS The 5 C s suggesting addiction during opioid Rx : Compulsive Use of Medication - frequent visits to ED, requesting drugs - family reports overuse, or intoxication

13 The 5 C s suggesting addiction during opioid Rx : Craving & PREOCCUPATION WITH OPIOIDS - failure to comply with non-drug therapies - failure to keep appointments - shows interest only in relief of symptoms, not rehabilitation - reports no effect from non-opioid Rx s - seeks meds from multiple physicians The 5 C s suggesting addiction during opioid Rx Concurrent use of mood altering drugs such as alcohol, marijuana, methamphetamine, or nonprescribed benzodiazepines by report, or UDS

14 We taper opioid using pain pts We detox opioid addicts since it is illegal to write an opioid Rx to treat opioid addiction, unless waivered to use Buprenorphine containing medication There are no such laws or provisions in CFR for BZD s, sedatives, or stimulants BZD

15 BZD WDS : Host factors Concurrent Medical Dx s Avoid BZD WDS during acute medical or surgical conditions, because of physiologic / adrenergic stress Risks of exacerbating the following conditions may outweigh the long-term benefits of BZD discontinuation : Principles of Addiction Medicine, 5th Ed., p. 658 BZD WDS : Host factors Concurrent Medical Dx s CAD / cardiac dysrhythmias / CV disease Asthma SLE Inflammatory bowel disease Severe NIDDM/IDDM Severe arthritis Severe thyroid disease Principles of Addiction Medicine, 5th Ed., p. 658

16 W I T H D R A W A L I N T E N S I T Y ACUTE WDS HIGH DOSE, ANY LOW DOSE SHORT ACTING LOW DOSE LONG ACTING PROLONGED POST ACUTE WDS (PAWS) DAYS MONTHS DURATION OF SEDATIVE HYPNOTIC / BZD WDS BZD & Other Sedative- Hypnotics : #1 = Taper method : - wean pt down by 10% starting dose - per week - for final 20% of the taper, - 5% starting dose q 2 weeks This obviously takes 3 months GOOD LUCK. Principles of Addiction Medicine, 5th Ed., p. 731

17 BZD Detox : I was trained on a 2 nd method for BZD s Clonazepam (as long as Pt < 3mg/d of clonazepam): - 1mg BID x 2 doses, then - 0.5mg BID x 2 doses, then mg BID x 2 doses, then DC Simultaneously begin divalproex or valproic acid : - 250mg QID for men - 250mg TID for women Check valproic acid level day #4 Principles of Addiction Medicine, 5th Ed., p BZD Detox/taper over 6 weeks (may want to cont valproate as mood stabilizer or for common migraine) The divalproex or valproic acid is tapered over 5 wks. Men : 250mg QID x 2 wks, then 250mg TID x 1 wks, then 250mg BID x 1 wks, then 250mg per day x 1 wk, then DC Women : 250mg TID x 3 wks, etc. Principles of Addiction Medicine, 5th Ed., p

18 BZD Detox/taper over 6 weeks (may want to cont valproate as mood stabilizer or for common migraine) Extend the initial clonazepam taper While starting the valproate, for pts who use long term, or very high doses of BZD s : Clonazepam : - 1mg q 12 hr x 2 doses, then - 0.5mg q 12 hr x 4 doses, then mg q 12 hr x 4 doses, then DC Use simultaneous valproate as indicated. Principles of Addiction Medicine, 5th Ed., p Substitute and taper If pt on lorazepam 0.5mg QID 1 st Month Taper to 2 lorazepam per day plus 1 divalproex 250mg or 1 valproic acid 250mg 2 nd Month Taper to 1 lorazepam per day plus divalproex 250mg BID Principles of Addiction Medicine, 5th Ed., p , 655

19 Substitute and taper If pt on lorazepam 0.5mg QID or less 3 rd Month (off lorazepam) pt is now on divalproex 250mg TID, then cont at that dose as mood stabilizer (or taper by 1 dose q 2 weeks) Principles of Addiction Medicine, 5th Ed., p , 655 Carisoprodol 350mg taper If more than 4 per day, taper by 2 pills per week until at 4/day Then taper by 1 dose per day per week Down to 1-2 per day, then DC and begin baclofen 10mg BID- TID Principles of Addiction Medicine, 5th Ed., p ,

20 CDC 90 MME per day Goal Dose, conversion factor,mme MS 90 mg x 1 = 90 MME Hydrocodone 60 mg x 1 = 60 MME Hydromorphone 12 mg x 4 = 48 MME Oxycodone 40 mg x 1.5 = 60 MME Fentanyl patch 25mcg/hr = 60 MME MTD 20mg x 3 = 60 MME Bup film/tab/buccal 2mg (2,000mcg) x 30 = 60 MME Bup weekly patch 20mcg/hr = 36 MME Motivation for Change: Discuss and Educate: CDC Guidelines and Consider Taper The previous basis of our treatment plan was that stable doses with reasonable pain control without loss of control (at nearly any dose) or harm is acceptable, but now they're telling us that anything above 90 MME is unacceptable.

21 Motivation for Change: Discuss and Educate: CDC Guidelines and Consider Taper Pt is educated about recent Pain Medication regulation changes that are being proposed AZ DHS Opioid Prescribing Guidelines contemplate that each pt should be on less than or equal to 90 MME per CDC 10/2016 Guidelines Motivation for Change: Discuss and Educate: CDC Guidelines and Consider Taper Pt can be educated that many people can have the same pain and less meds or no meds and less pain (due to hyperalgesia resolution). As of late 2017 we are anticipating changes and the need to approach the 10/2016 CDC Guidelines, even though it is retroactive in its application to many of our current Pts

22 Motivation to Change: Prescription may not be paid for by your insurance company insurance may interpret these guidelines as a reason to not pay for doses that are higher than 90 MME s First Opioid taper options: Taper by 1 ER/LA opioid Or Taper by 1 short acting opioid per day, over the next month until seen again continue the above Until 90 MME goal is reached.

23 First Opioid taper options: In the same manner as you would to increase by a small incremental dose Down taper just as would up-taper for someone asking for a higher analgesic dose First Opioid taper options: (each dose change lasts a month) If on MS ER 60mg BID, then MS ER 30mg TID, Then by 30mg BID Then 15mg BID

24 First Opioid taper options: (each dose change lasts a month) MS ER or IR doses over 180mg per day can usually per tapered to 180 quickly in mg downtaper monthly adjustments Then by 30mg per month average change Use symptomatic adjunctive meds, esp Buspirone or Tizanidine First Opioid taper options: (each dose change lasts a month) If on Oxycodone ER 40mg BID, then Oxycodone ER 30mg BID, then Oxycodone ER 20mg BID (60 MME) Oxycodone ER 10mg BID (30 MME)

25 First Opioid taper options: (each dose change lasts a month) If on Fentanyl patch 100 mcg/hr, then Fentanyl patch 75 mcg/hr, then Fentanyl patch 50 mcg/hr, then Fentanyl patch 25 mcg/hr, (60 MME) First Opioid taper options: (each dose change lasts a month) If on Oxymorphone ER 40mg BID, (240 MME) first convert to oxycodone mg for mg Oxycodone ER 40mg BID (120 MME) Oxycodone ER 30mg BID, then Oxycodone ER 20mg BID Oxycodone ER 10mg BID (30 MME)

26 First Opioid taper options: (each dose change lasts a month) If on Methadone for chronic pain Reduce dose by 5mg per day for the month If on MTD 10mg 6 per day (180 MME) Then 2 PO in AM, 2 PO noon, 1 & ½ in PM Then 2 PO in AM, 2 PO noon, 1 in PM, etc. down to MTD 10 mg 1 PO BID (60 MME) Or MTD 10 mg 1 PO TID (90 MME) Second option: 20 day Opioid taper off all opioids using 2 Rx s: Buprenorphine 2mg SL tab : first Rx, uses #20 tabs Bup 2mg SL tab 2 SL BID x 2 days (8mg/day..8,000mcg) Bup 2mg SL tab 1 SL TID x 2 days (6mg /day) Bup 2mg SL tab 1 SL BID x 2 days (4mg /day) Bup 2mg SL tab 1/2 SL BID x 2 days (2mg /day) Principles of Addiction Medicine, 5th Ed., p

27 Second part of 20 day Opioid taper Bup Transbuccal Film : Rx #2, uses #14 films Transbuccal Bup 450 mcg TID x 2 days (1.35mg/day) Transbuccal Bup 450mcg BID x 2 days Transbuccal Bup 450mcg ½ BID x 2 days Transbuccal Bup 450mcg ½ per day x 2 days Transbuccal Bup 450mcg ½ QOD x 2 doses (112 mcg) Then DC Principles of Addiction Medicine, 5th Ed., p Additional symptomatic Rx meds during opioid tapering 1. Quetiapine 50mg 1 PO HS for sleep 2. Trazodone 50mg 1 PO HS for sleep 3. Ibuprofen 600mg TID for arthralgias 4. Chlorzoxazone 500mg QID for myalgias 5. Ranitidine 150mg PO BID for dyspepsia

28 Additional symptomatic Rx meds during opioid tapering 5. Clonidine 0.1mg PO BID-TID for anxiety (Bp?) 6. Buspirone 5mg-10mg PO BID for anxiety 7. Immodium A-D 2 PO after loose BM (max 8/d) 8. Tizanidine 4mg PO TID for myalgias/cramps We ll end here, I m sure there s lots of questions Thanks so much! You ve been a great audience! Let s give the AOMA a big hand for this wonderful event!!

29 References: 1. In Principles of Addiction Medicine, 5th ed., (Ries, R.K., Fiellin, D.A., Miller, S.C., Saitz, R. Eds.) pp American Society of Addiction Medicine; Chevy Chase, Maryland

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful

More information

Tapering Opioids Best Practices*

Tapering Opioids Best Practices* Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G

More information

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes. Reference Guide for PACU Lumbar Fusion CLINICAL PATHWAY All patient variances to the pathway are to be circled and addressed in the progress notes. This Clinical Pathway is intended to assist in clinical

More information

ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment

ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment This booklet was created to help you learn about tapering. You probably have lots

More information

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program New Glasgow November 1, 2017 This speaker has been asked to disclose to the audience any involvement with

More information

New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) PDMP West Regional Meeting PMP Collaboration with the NM Department of Health April 26, 2018 New Mexico Board of Pharmacy Prescription

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)

1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW) Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer

More information

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter

More information

Legal Issues in Opioid Prescribing

Legal Issues in Opioid Prescribing Legal Issues in Opioid Prescribing Joanne L. Martin, J.D. Legal Counsel Mayo Clinic Rochester, Mn 2015 MFMER slide-1 Conflict of Interest I have no relevant financial relationships to disclose I will not

More information

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

D. Janene Holladay, M.D. Board Certifications: American Board of Anesthesiology American Board of Pain Medicine American Board of Addiction Medicine

D. Janene Holladay, M.D. Board Certifications: American Board of Anesthesiology American Board of Pain Medicine American Board of Addiction Medicine D. Janene Holladay, M.D. Board Certifications: American Board of Anesthesiology American Board of Pain Medicine American Board of Addiction Medicine Financial Disclosure I have no relevant financial relationships

More information

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures

Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM Disclosures Dr. Bhatnagar: no disclosures to report Dr. Ewing: no disclosures to report 1 Our

More information

Knock Out Opioid Abuse in New Jersey:

Knock Out Opioid Abuse in New Jersey: Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids

More information

Difficult Conversations

Difficult Conversations Difficult Conversations D R. L Y D I A A N N E M B A R T H O L O W, D N P, P M H N P, C A R N - AP Skill Building Patient centered Boundaries and self-protection Trauma informed Care 1 Skill Building Trauma

More information

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013

Management of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial

More information

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline

Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months

More information

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin

More information

Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies. 9/20/17

Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies.   9/20/17 You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies Jeffrey Fudin, BS, PharmD, FCCP, FASHP www.paindr.com Disclosures Astra Zeneca (Speakers Bureau) Collegium (Consultant) Daiichi

More information

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Virginia. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

Steven Prakken MD Director Medical Pain Service Duke Pain Medicine

Steven Prakken MD Director Medical Pain Service Duke Pain Medicine Steven Prakken MD Director Medical Pain Service Duke Pain Medicine Misuse Abuse Addiction Total Pain Population Webster LR, Webster RM. Pain Med. 2005;6(6):432-442. DSM IV Abuse defined as 2 elements

More information

Welcome to the Opioid Overdose Prevention Project

Welcome to the Opioid Overdose Prevention Project Welcome to the Opioid Overdose Prevention Project Narcan Training TODAY S OBJECTIVES Define drug addiction Identify symptoms of addiction Treatment options including support for family members How to recognize

More information

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days

More information

ORAL MEDS FOR PAIN. Pain Tolerance 4/11/2018

ORAL MEDS FOR PAIN. Pain Tolerance 4/11/2018 ORAL MEDS FOR PAIN Pain Tolerance Varies with each individual Signs usually should match symptoms Have compassion but don t panic when someone appears to be in pain 1 The Psychology of Pain A firm, calm,

More information

APPENDIX E: HEALTHCARE PRACTITIONER- REPORTED REDUCTION OF PAIN MEDICATION

APPENDIX E: HEALTHCARE PRACTITIONER- REPORTED REDUCTION OF PAIN MEDICATION Contents Appendix E: Healthcare Practitioner-Reported Reduction of Pain Medication... E-1 Appendix E: Healthcare Practitioner- Reported Reduction of Pain Medication Note: Word choice and spellings have

More information

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures

More information

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be

More information

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D. Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals

More information

Welcome - we will begin the webinar shortly Please read the participation tips below:

Welcome - we will begin the webinar shortly Please read the participation tips below: Welcome - we will begin the webinar shortly Please read the participation tips below: All guest phones have been muted: Background noises, conversations, white noise etc., can be disruptive to a webinar.

More information

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program North Sydney April 12, 2018 This speaker has been asked to disclose to the audience any involvement with

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

Analgesics: Management of Pain In the Elderly Handout Package

Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed

More information

4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t

4/3/2018. Management of Acute Pain Crises. Five Mistakes I ve made and why you shouldn t Management of Acute Pain Crises Maggie O Connor, M.D. Retired Palliative Care Physician Hope is not the conviction that something will turn out well, but the certainty that something makes sense, regardless

More information

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities Svetla Slavova, PhD Sara LaMantia, MS Terry Bunn, PhD Tracey Corey, MD 2016 Safe States Annual Meeting April 13, 2016, Albuquerque,

More information

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D.

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D. 1/25/17 PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D. PISA Physicians Kenneth B. Gossler M.D. Education University of Arizona Med School 1992. THMEP Intern 1993 Anesthesiology Residency at Financial

More information

The Difficult Patient: Risk Mitigation Strategies

The Difficult Patient: Risk Mitigation Strategies The Difficult Patient: Risk Mitigation Strategies C. Scott Anthony, D.O. Pain Management of Tulsa 1 Opioid Backlash National emergency Opioids not indicated for chronic pain Forces pushing for reduction

More information

Proposed Revision to Med (i)

Proposed Revision to Med (i) Proposed Revision to Med 501.02 (i) I. Purpose This rule has been adopted to enable the Board to best protect public health and safety while providing a framework for licensees to effectively treat and

More information

California. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Chronic Pain, Opioids, & Addiction: Assessing and Managing Risk

Chronic Pain, Opioids, & Addiction: Assessing and Managing Risk Chronic Pain, Opioids, & Addiction: Assessing and Managing Risk Randy Brown MD, PhD, FASAM Associate Professor, Dept of Family Medicine Director, Center for Addictive Disorders, UWHC Director, UW Addiction

More information

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine The purpose of this agreement is to give you information about the medications you will be taking for

More information

Vermont Hub and Spoke Model Treatment Need Questionnaire

Vermont Hub and Spoke Model Treatment Need Questionnaire Vermont Hub and Spoke Model Treatment Need Questionnaire Friday, June 30, 2017 John Brooklyn, MD Assistant Professor of Family Medicine and Psychiatry University of Vermont Burlington, Vermont Webinar

More information

The Dark Art. Of Supervising & Managing Controlled Substances

The Dark Art. Of Supervising & Managing Controlled Substances The Dark Art Of Supervising & Managing Controlled Substances David A. Frenz, M.D. Vice President & Executive Medical Director North Memorial Health Care Robbinsdale, Minn. 27 October 2016 www.doctorfrenz.com

More information

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER

More information

John Murphy DO, MS Lynx Healthcare

John Murphy DO, MS Lynx Healthcare Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior

More information

Goals for sedation during mechanical ventilation

Goals for sedation during mechanical ventilation New Uses of Old Medications Gina Riggi, PharmD, BCCCP, BCPS Clinical Pharmacist Trauma ICU Jackson Memorial Hospital Disclosure I do not have anything to disclose Objectives Describe the use of ketamine

More information

Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015

Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015 Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use

More information

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine Pain Management Wrap-Up Chronic Care David Tauben, MD Medicine Anesthesia & Pain Medicine Objectives Understand that Pain is Complex Know how to select Rx based on Pain type Be aware that Rx only reduces

More information

Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder

Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM Preventative Education: Substance Use Disorder Misuse of prescription pain relievers is, after marijuana use, the second most common form of

More information

Steven Prakken MD Chief, Medical Pain Service Duke Pain Medicine

Steven Prakken MD Chief, Medical Pain Service Duke Pain Medicine Steven Prakken MD Chief, Medical Pain Service Duke Pain Medicine International Association for the Study of Pain "Pain is an unpleasant sensory and emotional experience associated with actual or potential

More information

Subject: Pain Management (Page 1 of 7)

Subject: Pain Management (Page 1 of 7) Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all

More information

PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION. Chronic Pain and Opiate Management Initiatives

PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION. Chronic Pain and Opiate Management Initiatives PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION Chronic Pain and Opiate Management Initiatives Objectives To enhance understanding of current concepts, guidelines and risks of

More information

National Council on Patient Information and Education

National Council on Patient Information and Education National Council on Patient Information and Education You are not alone The type of pain that caused your doctor to prescribe a pain medicine for you can make you feel that you are different from everyone

More information

Poisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents ( )

Poisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents ( ) Source: National Vital Statistics Poisoning Deaths vs. Motor Vehicle Related Injury Deaths, MA Residents (1997 2008) The source of the data is: Registry of Vital Records and Statistics, MA Department of

More information

Managing Pain in Individuals with Serious Illness and Comorbid Substance Use Disorder

Managing Pain in Individuals with Serious Illness and Comorbid Substance Use Disorder Managing Pain in Individuals with Serious Illness and Comorbid Substance Use Disorder Presented by: Kathleen Broglio, DNP, ANP-BC, ACHPN, CPE, FPCN on December 1, 2016 Webcast Questions and Answers (Answers

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Safe Prescribing of Drugs with Potential for Misuse/Diversion College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines

More information

Opioid Initiative Wave I Treating Opioid-Use Disorder in the ED Part 1

Opioid Initiative Wave I Treating Opioid-Use Disorder in the ED Part 1 Opioid Initiative Wave I Treating Opioid-Use Disorder in the ED Part 1 Presenter Eric Ketcham, MD, MBA Reuben J. Strayer, MD emergency department management of the patient with opioid withdrawal OD is

More information

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Dr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force

Dr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force Dr. Smith Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force 1 1 How We Got Here 2 The Epidemic 3 4 San Diego Death Diaries

More information

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Medication-Assisted Treatment. What Is It and Why Do We Use It? Medication-Assisted Treatment What Is It and Why Do We Use It? What is addiction, really? o The four C s of addiction: Craving. Loss of Control of amount or frequency of use. Compulsion to use. Use despite

More information

1/30/2017 SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT ACPE PRE-TEST QUESTIONS. I have no declarations.

1/30/2017 SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT ACPE PRE-TEST QUESTIONS. I have no declarations. SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT Traci Hamer, PharmD, MAT Kaiser Permanente Northwest Pain Management Pharmacy Services I have no declarations. ACPE PRE-TEST QUESTIONS True/False: Opioids

More information

Addiction Medicine: What s new for primary care

Addiction Medicine: What s new for primary care Addiction Medicine: What s new for primary care Dan Vinson, MD Family and Community Medicine How to talk so our patients listen, and listen so our patients talk. 1 2 Comfortably engaging your patient in

More information

6/27/2017. Disclosures. Overview. Case Overview

6/27/2017. Disclosures. Overview. Case Overview Disclosures Jessica Gray, MD Nothing to disclose Daniel Alford, MD, MPH Nothing to disclose John Renner, MD Overview The intersection of active illicit opioid use, acute pain and severe mental illness

More information

PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018

PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018 PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018 TAPERING OPIOIDS GETTING STARTED ON OPIOIDS IS EASY BUT GETTING PATIENTS OFF IS HARD WE ARE ARE OBLIGED TO TAPER PATIENTS DOWN AND OFF OPIOIDS

More information

Prescription Opioid Addiction

Prescription Opioid Addiction CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett

More information

Opioid dependence and buprenorphine treatment

Opioid dependence and buprenorphine treatment Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions

More information

New Guidelines for Opioid Prescribing

New Guidelines for Opioid Prescribing New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research

More information

Substitution Therapy for Opioid Use Disorder The Role of Suboxone

Substitution Therapy for Opioid Use Disorder The Role of Suboxone Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM

More information

Fighting the Good Fight: How to Convert Opioids Just Right!

Fighting the Good Fight: How to Convert Opioids Just Right! Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,

More information

Opioid Conversions Mixture of Science and Art

Opioid Conversions Mixture of Science and Art Opioid Conversions Mixture of Science and Art Matthew J. Pingree, MD Assistant Professor Division of Pain Medicine Physical Medicine and Rehabilitation and Anesthesiology Mayo Clinic, Rochester Pingree.Matthew@Mayo.edu

More information

Testing for Controlled Substances

Testing for Controlled Substances Testing for illicit drugs Testing for Controlled Substances 1 Purposes: Employment Sports Screening medical eval. Legal Monitoring Treatment Probation Prescribing controlled substances Forensics 2 Drug

More information

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

The Role of the Emergency Department in the Opioid Epidemic. Scott G. Weiner, MD, MPH Department of Emergency Medicine Brigham and Women s Hospital

The Role of the Emergency Department in the Opioid Epidemic. Scott G. Weiner, MD, MPH Department of Emergency Medicine Brigham and Women s Hospital The Role of the Emergency Department in the Opioid Epidemic Scott G. Weiner, MD, MPH Department of Emergency Medicine Brigham and Women s Hospital Disclosures Treasurer, Massachusetts College of Emergency

More information

solutions MEDICATION MIS MANAGEMENT and Chronic Pain 10/4/2016 Opioid Abuse: Current Data Opioid Abuse: Current Data

solutions MEDICATION MIS MANAGEMENT and Chronic Pain 10/4/2016 Opioid Abuse: Current Data Opioid Abuse: Current Data MEDICATION MIS MANAGEMENT and Chronic Pain solutions Opioid Abuse: Current Data Americans consume 80% of the global supply of opioids This includes 99% of the world s hydrocodone and 2/3s of the world

More information

OBSERVATION SHEET TOPIC CLINICAL SCENARIO. OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation)

OBSERVATION SHEET TOPIC CLINICAL SCENARIO. OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation) OBSERVATION SHEET TOPIC CLINICAL SCENARIO OBSERVATIONS MADE (Use the skills objectives/ provider tasks to evaluate the conversation) FEEDBACK: WHAT WENT WELL FEEDBACK: THINGS TO CONSIDER DEBRIEF: Observer

More information

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,

More information

Behavioral Health in PACE: Substance Abuse

Behavioral Health in PACE: Substance Abuse Behavioral Health in PACE: Substance Abuse NPA s Quality Symposium 2017 June 9th, 2017 Bharati Srivastava MD MBA FACP AGSF Mercy LIFE Sharon Hill Mercy LIFE Southeastern PA Trinity Health Inc. Objectives

More information

Controlled Substance and Wellness Agreement

Controlled Substance and Wellness Agreement Controlled Substance and Wellness Agreement You and your provider have agreed on the use of controlled substance medications to treat your: We want to make sure you know how to manage your new prescription(s)

More information

Opioid Prescribing Guidelines for Patients in the Emergency Department

Opioid Prescribing Guidelines for Patients in the Emergency Department Opioid Prescribing Guidelines for Patients in the Emergency Department and Immediate Care Centers These guidelines are meant to assist clinicians in treating patients with acute and chronic pain in the

More information

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Opioid Analgesics. Recommended starting dose for opioid-naïve patients Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Source: National Vital Statistics

Source: National Vital Statistics Summarize the basics of how to wean patients off of opiates and who is at risk of withdrawal. Review the signs and symptoms of withdrawal from chronic opioids. Summarize how providers can use medications

More information

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

Vermont. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of

More information

TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: LAST REVISED DATE: LAST REVIEWED DATE:

TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: LAST REVISED DATE: LAST REVIEWED DATE: TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: 4.19.16 LAST REVISED DATE: 4.19.16 LAST REVIEWED DATE: 4.19.16 Table of Contents 1. How do I conduct my first few visits with a patient who

More information

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,

More information

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners, Albany, NY Assistant Professor of Medicine,

More information

Montgomery County Poisoning Death Review:

Montgomery County Poisoning Death Review: Wright State University CORE Scholar Unintentional Prescription Drug Poisoning Project Center for Interventions, Treatment and Addictions Research 5-6-214 Montgomery County Poisoning Death Review: 21-213

More information

Disclosures. Get Your Specimens in Order:

Disclosures. Get Your Specimens in Order: Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Jennifer Bolen, JD Disclosures Jennifer Bolen, JD Consultant to Generation Partners Consultant to Abbott

More information

Opioid Induced Hyperalgesia (OIH)

Opioid Induced Hyperalgesia (OIH) Opioid Induced Hyperalgesia (OIH) How to Receive Your CE Credits Read your selected course Completed the quiz at the end of the course with a 70% or greater. Complete the evaluation for your selected course.

More information

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids

MAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the

More information

15mg oxycodone is equivalent to how much morphine

15mg oxycodone is equivalent to how much morphine 15mg oxycodone is equivalent to how much morphine The Borg System is 100 % 15mg oxycodone is equivalent to how much morphine nursing home activity director cover letter 15 mg oxycodone equal to how much

More information

Pain CONCERN. Medicines for long-term pain. Opioids

Pain CONCERN. Medicines for long-term pain. Opioids Pain CONCERN Medicines for long-term pain Opioids Opioids are a group of medicines that come from the extract of poppy seeds or other medicines that work in the same way. Types of opioid The first opioids

More information

Treatment of Pain in an Emergent Setting

Treatment of Pain in an Emergent Setting Updated: October 22, 2018 Prescribing Guidelines for Pennsylvania Treatment of Pain in an Emergent Setting Opioids, including heroin and fentanyl, contribute to thousands of overdose deaths in Pennsylvania

More information

Discover the Hope: Opiate Treatment and Recovery

Discover the Hope: Opiate Treatment and Recovery Discover the Hope: Opiate Treatment and Recovery The Continued Struggle to Find and Implement Best Practices Ted Parran JR. M.D. FACP Carter and Isabel Wang Professor of Medical Education CWRU School of

More information

Chronic Opioid Therapy Safe Prescribing in Primary Care. Part 3

Chronic Opioid Therapy Safe Prescribing in Primary Care. Part 3 Chronic Opioid Therapy Safe Prescribing in Primary Care Part 3 Michael Mangione, MD Chief of Anesthesia and Director of Pain Service VA Pittsburgh Health Care System Nancy Wiedemer,CRNP VISN 4 Pain Management

More information